Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.

Ming-Hao Xu,Cheng Huang,Mei-Ling Li,Xiao-Dong Zhu,Chang-Jun Tan,Jian Zhou,Jia Fan,Hui-Chuan Sun,Ying-Hao Shen

Cancer medicine（2023）

引用 1|浏览33

暂无评分

摘要

Lenvatinib combined with anti-PD-1 antibody therapy was effective in patients with sufficient liver function reserve. Further study is needed to improve therapeutic efficacy and AE management in patients with Child-Pugh class B or ALBI grade 2/3.

查看译文

关键词

ALBI grade,Child-Pugh class,anti-PD-1 antibody,hepatocellular carcinoma,lenvatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要